Shay Shemesh - 08 Feb 2022 Form 3 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Role
Chief Development Officer
Signature
/s/ Shay Shemesh
Issuer symbol
NVCT
Transactions as of
08 Feb 2022
Net transactions value
$0
Form type
3
Filing time
08 Feb 2022, 07:37:58 UTC
Previous filing
08 Feb 2022
Next filing
05 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NVCT Common Stock 1,176,669 08 Feb 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 48,399 shares of restricted stock issued pursuant to Mr. Shemesh's employment arrangement upon the consummation of a $15.3 million private equity financing. This restricted stock award (RSA) vests on July 27, 2022, one year after the grant date.